A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA). (2022)

First Author: Stewart GD
Attributed to:  Cambridge Mathematics of Information in Healthcare (CMIH) funded by EPSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1038/s41416-022-01883-7

PubMed Identifier: 35739300

Publication URI: http://europepmc.org/abstract/MED/35739300

Type: Journal Article/Review

Volume: 127

Parent Publication: British journal of cancer

Issue: 6

ISSN: 0007-0920